title: Long-term ganciclovir therapy for hepatitis B virus infection after liver transplantation.
abstract: OBJECTIVE
  Hepatitis B virus (HBV) disease on a liver graft is associated with florid viral replication and graft failure. The aim of this study performed between 1992 and 1995 was to investigate the safety and efficacy of long-term intravenous ganciclovir for HBV infection in liver transplant recipients.
  
  
  METHODS
  Twelve patients with HBV re-infection and four with de novo HBV infection were studied. HBV DNA was positive in all (median titer: 437.5 pg/ml) and HBeAg was positive in seven. Intravenous ganciclovir was started after a median of 14.5 months from HBsAg positivation and continued for a median of 10 months.
  
  
  RESULTS
  A complete response with HBV DNA negativation was seen in ten cases, a partial response with a decrease of more than 50% of initial HBV DNA levels in four and no response in two. Overall tolerance was good. Among the ten complete responders, two seroconverted for both HBsAg and HBeAg and one for HBsAg alone. Among these ten patients, three were re-transplanted for liver failure: two of them are alive; three had a viral breakthrough during treatment; and four remained HBV DNA negative: two are alive and two died. Partial responders and nonresponders were treated with other antiviral agents and three were re-transplanted, two of them are alive. Overall 12 out of 16 patients (75%) survived with a median follow up of 46 months.
  
  
  CONCLUSIONS
  Long-term intravenous ganciclovir can persistently inhibit HBV DNA replication in liver transplant recipients and is well tolerated. Further evaluation should be encouraged, especially for HBV recurrence after first-line treatments.
authors.affiliation: Centre Hépato-Biliaire, Hôpital Paul Brousse, Faculté de Médecine Paris-Sud, Contrat de Recherche INSERM 98-04, UPRES Foie, Virus Hépatotropes et Cancer, Villejuif, France.
authors.forename: B
authors.initials: B
authors.lastname: Roche
authors.forename: D
authors.initials: D
authors.lastname: Samuel
authors.forename: M
authors.initials: M
authors.lastname: Gigou
authors.forename: C
authors.initials: C
authors.lastname: Feray
authors.forename: V
authors.initials: V
authors.lastname: Virot
authors.forename: P
authors.initials: P
authors.lastname: Majno
authors.forename: L
authors.initials: L
authors.lastname: Serraf
authors.forename: M F
authors.initials: MF
authors.lastname: David
authors.forename: E
authors.initials: E
authors.lastname: Dusseaix
authors.forename: M
authors.initials: M
authors.lastname: Reynes
authors.forename: H
authors.initials: H
authors.lastname: Bismuth
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000009:adverse effects / Q000627:therapeutic use*; D004279:DNA, Viral / Q000032:analysis; D005260:Female; D015774:Ganciclovir / Q000009:adverse effects / Q000627:therapeutic use*; D006509:Hepatitis B / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D006511:Hepatitis B Antigens / Q000032:analysis; D006515:Hepatitis B virus / Q000235:genetics; D006801:Humans; D008099:Liver / Q000473:pathology; D016031:Liver Transplantation; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000188:drug therapy*; D011446:Prospective Studies; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents; D004279:DNA, Viral; D006511:Hepatitis B Antigens; D015774:Ganciclovir